PHARMADAN A/S: Financial statements 2023
CVR: 26524938
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
PHARMADAN A/S (CVR 26524938) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -4,923,093 and a net result of DKK -4,167,683 compared with DKK -2,752,872 the year before. Equity in the 2023 report amounted to DKK -8,414,873.
- Gross Profit
- DKK -4,923,093
- Profit/Loss
- DKK -4,167,683
- Equity
- DKK -8,414,873
- Total Assets
- DKK 4,517,687
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -4.9M | -4.2M | -8.4M | - |
| 2022 | - | -3.1M | -2.8M | -4.2M | - |
| 2021 | - | -2.8M | -2.5M | -1.5M | - |
| 2020 | - | -8K | -1.6M | 1M | 3 |
| 2019 | - | 956K | -800K | 2.6M | 3 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationAbout PHARMADAN A/S
PHARMADAN A/S is a Danish company of the type Aktieselskab based in Kastrup, founded in 2002. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Peter Rørvig. The board consists of Helle Rørvig, Niels Ulrik Heine and Peter Rørvig. The company is owned by H&P Rørvig Holding A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -6,382,654 and a net result of DKK -5,426,641 compared with DKK -5,113,611 the year before. Equity in the 2025 report amounted to DKK -18,955,125.